RARE DISEASERESEARCH ATLAS

ORPHA:97238

Rippling muscle disease

medium confidenceDisorder

Publications

258

68.8th percentile

Trials

0

Interventional, condition-specific

Researchers

1,188

Distinct authors in sample

Gene link

Readiness

1/6

Stages with a signal

Clinical definition (Orphanet)

Rippling muscle disease is a rare, genetic, neuromuscular disorder characterized by muscle hyperirritability triggered by stretch, percussion or movement. Patients present wave-like, electrically-silent muscle contractions (rippling), muscle mounding, painful muscle stiffness and muscle hypertrophy, usually with elevated serum creatine kinase.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

1/6 stages with a signal

Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    258 matched papers (115 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

258

258 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

258 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

115 in the last 10 years · medium confidence · 68.8th percentile (publications denominator)

Phrase hits: 258 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,188

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Minetti C10 papers · 2022

    Department of Pediatrics, Neuromuscular Disease Unit, Gaslini Pediatric Hospital, University of Genova, Genova, Italy

    Papers in Europe PMC
  2. 02
    Vorgerd M9 papers · 2023

    Department of Neurology, Ruhr-University, Bochum, Germany. matthias.vorgerd@ruhr-uni-bochum.de

    Papers in Europe PMC
  3. 03
    Kubisch C8 papers · 2009

    Institute of Human Genetics, University of Bonn, Bonn, Germany.

    Papers in Europe PMC
  4. 04
    Lisanti MP8 papers · 2010

    Department of Biochemistry and Molecular Biology, Jefferson Medical College;, Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania

    Papers in Europe PMC
  5. 05
    Sotgia F8 papers · 2010

    Departments of Molecular Pharmacology and Cell Biology, and The Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York 10461, USA.

    Papers in Europe PMC
  6. 06
    Dubey D7 papers · 2026

    Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota.

    Papers in Europe PMC
  7. 07
    Liewluck T7 papers · 2025

    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA.

    Papers in Europe PMC
  8. 08
    Milone M7 papers · 2025

    Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA. milone.margherita@mayo.edu

    Papers in Europe PMC
  9. 09
    Straub V7 papers · 2022

    John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, Newcastle University, Centre for Life, Newcastle, United Kingdom.

    Papers in Europe PMC
  10. 10
    Ricker K6 papers · 2002

    Department of Neurology, University of Würzburg, West Germany.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

medium confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Rippling muscle disease"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Rippling muscle disease"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (258) is high for prevalence class "<1 / 1 000 000" — confidence capped at medium

Ingested 2026-07-27T05:03:23.879Z